Panel of 48 CSF Proteins Complements Existing Alzheimer Biomarkers
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Sept. 7, 2023 -- A panel of 48 proteins in the cerebrospinal fluid (CSF 48 panel) complements existing CSF biomarkers for Alzheimer disease (AD), according to a study published in the Sept. 6 issue of Science Translational Medicine.
Rafi Haque, M.D., Ph.D., from the Emory University School of Medicine in Atlanta, and colleagues developed a reliable and high-throughput mass spectrometry-selected reaction monitoring assay that targets 48 key proteins altered in the CSF, as identified in previous work. The diagnostic utility of the protein panel was examined in CSF collected at baseline visits from 706 participants recruited from the Alzheimer’s Disease Neuroimaging Initiative (ADNI).
The researchers found that at least as good performance was seen for the CSF 48 panel as compared with existing AD CSF biomarkers (amyloid β42, tTau, and pTau181) for predicting clinical diagnosis, fluorodeoxyglucose (FDG), positron emission tomography (PET), hippocampal volume, and measures of cognitive and dementia severity. The CSF 48 panel plus the existing AD CSF biomarkers significantly improved diagnostic performance for each of these outcomes. Compared with either measure alone, the CSF 48 panel plus existing AD CSF biomarkers significantly improved predictions for changes in FDG PET, hippocampal volume, and measures of cognitive decline and dementia severity.
"The CSF 48 panel improves upon existing AT(N) [amyloid plaques, neurofibrillary tangles, and neurodegeneration] biomarkers to predict many pathophysiological mechanisms linked to AD and AD-related dementia brain; distinguish pathophysiological mechanisms based on their proteomic signature; and improve the prediction of disease progression and future changes in cognition, dementia severity, and hippocampal volume," the authors write.
ADNI was partially supported by pharmaceutical companies.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Higher Olive Oil Intake Tied to Lower Risk for Dementia-Related Death
WEDNESDAY, May 8, 2024 -- Higher olive oil intake is associated with a lower risk for dementia-related mortality in U.S. adults, according to a study published online May 6...
Benefit of Thick Liquids in Alzheimer Disease and Dysphagia Unclear
MONDAY, May 6, 2024 -- For hospitalized patients with Alzheimer disease and related dementias (ADRD) and dysphagia, those receiving thick liquids are less likely to be intubated...
Cognitive Impairment Still Seen in Children, Teens With HIV
TUESDAY, April 30, 2024 -- Cognitive impairment persists in children and adolescents living with HIV even in the era of antiretroviral therapy (ART), according to research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.